Clinical Manifestations of Lyme Borreliosis in Europe: Burden of Lyme Disease Study (BOLD), 2021–2022
Pathogens · 18.03.2026 · 15 (3) · 327
DOI: 10.3390/pathogens15030327 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pathogens, online erschienen am 18.03.2026. Verfasst von Kate Halsby und 14 weiteren Autor:innen. Beteiligte Einrichtung: Pfizer Ltd., Dorking Road, Tadworth, Surrey KT20 7NS, UK. Hauptthemen laut MEDLINE: Lyme Disease. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Pfizer (United States), Valneva (Austria).
Abstract (Originalsprache)
Lyme borreliosis (LB), the most common European tick-borne disease, can manifest as an erythema migrans (EM) rash or as disseminated LB. The prospective Burden of Lyme Disease (BOLD) study evaluated the frequency of LB clinical manifestations, including signs, symptoms, and treatment patterns in 14 healthcare practices in endemic regions of six European countries: the Czech Republic, Germany, Poland, Slovakia, Slovenia, and Sweden. Between April 2021 and December 2022, patients with suspected LB were evaluated using predefined case definitions that were applied by investigators to identify medically attended LB cases. Enrolled cases were interviewed about their symptoms. Among the 797 LB cases, 615 (77.2%) had EM and 182 (22.8%) had disseminated disease; 154 of the disseminated cases had Lyme arthritis (LA), five had Lyme neuroborreliosis, and three had Lyme carditis. Geographically, the proportion of disseminated disease varied by country, from 1.1% in Slovenia to 78.0% in Slovakia. Overall, 76.3% of all LB cases in Slovakia were LA. Antibiotic use varied by country, although every country prescribed doxycycline. The frequency of LB manifestations varied substantially between countries. EM was the most common manifestation in all countries except Slovakia, where LA was most common. This study underscores the need for improved prevention strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pfizer Ltd., Dorking Road, Tadworth, Surrey KT20 7NS, UK.
- Pfizer Corporation Austria GmbH, Floridsdorfer Hauptstraße 1, 1210 Wien, Austria.
- Department of Infectious Diseases, University Medical Centre Ljubljana, Japljeva 2, 1525 Ljubljana, Slovenia.
- Department of Infectious Diseases and Neuroinfections, Medical University of Bialystok, ul. Zurawia 14, blok D, 15-540 Bialystok, Poland.
- Department of Health, Blekinge Institute of Technology, Valhallavägen 1, 371 79 Karlskrona, Sweden.
- MUDr. Viliam Cibik, PhD, s.r.o., Vseobecna Ambulancia pre Dospelych, Pruské 293, 018 52 Pruské, Slovakia.
ORCID-Profile: Alexandra Loew-Baselli, Franc Strle, Anna Moniuszko-Malinowska, Johan Sanmartin Berglund, Andreas Pilz, Brad D Gessner, Elizabeth Begier
Förderung
- Pfizer (United States)
- Valneva (Austria)
Zitieren
APA
Halsby, K., Loew-Baselli, A., Strle, F., Moniuszko-Malinowska, A., Berglund, J. S., Cibik, V., Zakova, D., Tan, Y., Angulo, F. J., Edwards, J., Pilz, A., Gessner, B. D., Begier, E., Stark, J. H., & On Behalf Of The Bold Study Group (2026). Clinical Manifestations of Lyme Borreliosis in Europe: Burden of Lyme Disease Study (BOLD), 2021–2022. Pathogens, 15(3), 327. https://doi.org/10.3390/pathogens15030327
Vancouver
Halsby K, Loew-Baselli A, Strle F, Moniuszko-Malinowska A, Berglund JS, Cibik V, et al. Clinical Manifestations of Lyme Borreliosis in Europe: Burden of Lyme Disease Study (BOLD), 2021–2022. Pathogens. 2026;15(3):327. doi:10.3390/pathogens15030327
BibTeX
@article{Halsby2026,
author = {Halsby, Kate and Loew-Baselli, Alexandra and Strle, Franc and Moniuszko-Malinowska, Anna and Berglund, Johan Sanmartin and Cibik, Viliam and Zakova, Dagmar and Tan, Ye and Angulo, Frederick J and Edwards, Juanita and Pilz, Andreas and Gessner, Brad D and Begier, Elizabeth and Stark, James H and On Behalf Of The Bold Study Group},
title = {Clinical Manifestations of Lyme Borreliosis in Europe: Burden of Lyme Disease Study (BOLD), 2021–2022},
journal = {Pathogens},
year = {2026},
volume = {15},
number = {3},
pages = {327},
doi = {10.3390/pathogens15030327}
}
EUVIMED